Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

تهیه نانو واکسن نوترکیب نوروتوکسین بوتولینوم تیپ E بر پایه کیتوسان و مقایسه ایمنی‌زایی آن به دو روش تزریقی و خوراکی در موش سوری

Background and Objectives: Botulism syndrome is caused by one of the seven botulinum neurotoxins. The toxins binding domain have immunogenicity effect and can be used as a recombinant vaccine candidate against botulism disease. Due to the low immunogenicity of recombinant protein , the use of an appropriate vehicle for antigen delivery to target cells is inevitable. The purpose of this study ...

Immunogenic and Protective Potentials of Recombinant Receptor Binding Domain and a C-Terminal Fragment of Clostridium botulinum Neurotoxin Type E

Clostridium Botulinum Type E neurotoxin heavy chain consists of two domains: the translocation domain asthe N-terminal half and the binding domain as the Cterminal half (Hc). One effective way to neutralize botulinum neurotoxin is to inhibit binding of this toxin to neuromuscular synapses with antibodies against binding domain. Two synthetic genes, coding for Hc (the full length binding d...

Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo

Botulinum neurotoxins are one of the most potent toxins found in nature, with broad medical applications from cosmetics to the treatment of various neuropathies. Additionally, these toxins are classified as Category A-Tier 1 agents, with human lethal doses calculated at as little as 90 ng depending upon the route of administration. Of the eight distinct botulinum neurotoxin serotypes, the most ...

Cloning, Expression and Purification of Clostridium botulinum Neurotoxin Type E Binding Domain

Comparative Study of Immunological and Structural Properties of Two Recombinant Vaccine Candidates against Botulinum Neurotoxin Type E

Background: Recently, botulinum neurotoxin (BoNT)-derived recombinant proteins have been suggested as potential botulism vaccines. Here, with concentrating on BoNT type E (BoNT/E), we studied two of these binding domain-based recombinant proteins: a multivalent chimer protein, which is composed of BoNT serotypes A, B and E binding subdomains, and a monovalent recombinant protein, which contains...